Posted by Michael Wonder on 09 Aug 2024
BioMarin announces updated strategy for Roctavian to focus on US, Germany and Italy
5 August 2024 - Strategic focus will reduce operating expenses with the goal of achieving Roctavian profitability by end of 2025.
BioMarin Pharmaceutical today announced it will make changes to its Roctavian business to focus commercial operations on three markets, the United States, Germany and Italy, where the medicine is approved and reimbursed as a treatment for severe haemophilia A. BioMarin will adjust its Roctavian efforts across the company, reducing additional investments in development and manufacturing.
